Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer

Clinical trial NCT07718854 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07718854
Sponsor: Tufts Medical Center
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Ovarian Clear Cell Carcinoma Metastatic Ovarian Cancer Recurrent Ovarian Clear Cell Adenocarcinoma

Start date: 2026-06-01
Primary completion: 2032-03-01
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.